Shanghai Haoyuan Chemexpress (688131) Fundamentals 2026 — P/E 61.5x, Revenue Analysis | SniperIQ
Shanghai Haoyuan Chemexpress (688131) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥15.1B, trading at ¥71.00 on the SHH. This SniperIQ fundamentals page covers Shanghai Haoyuan Chemexpress's valuation (P/E 61.5x, P/B 4.7x), profitability (net margin 8.2%), revenue (¥2.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Haoyuan Chemexpress's market cap?
Shanghai Haoyuan Chemexpress (688131) has a market capitalization of approximately ¥15.1B, trading at ¥71.00 on the SHH. Market cap moves with the live share price.
What is Shanghai Haoyuan Chemexpress's P/E ratio?
Shanghai Haoyuan Chemexpress's trailing twelve-month P/E ratio is 61.5x, with a price-to-book (P/B) of 4.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Haoyuan Chemexpress?
Shanghai Haoyuan Chemexpress runs a net profit margin of 8.2%, a gross margin of 47.6%, and an operating margin of 13.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Haoyuan Chemexpress generate?
Shanghai Haoyuan Chemexpress reported revenue of ¥2.9B for fiscal year 2025, with net income of ¥240M and earnings per share (EPS) of 1.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Haoyuan Chemexpress pay a dividend?
Shanghai Haoyuan Chemexpress offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Haoyuan Chemexpress financially healthy?
Shanghai Haoyuan Chemexpress carries a debt-to-equity ratio of 0.68x and a current ratio of 2.16x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Haoyuan Chemexpress a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Haoyuan Chemexpress (688131) the key facts are: market cap ¥15.1B, P/E 61.5x, revenue ¥2.9B, 52-week range 51.93-99.97. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Haoyuan Chemexpress's full fundamentals live
Get Shanghai Haoyuan Chemexpress's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.